Pumitamig Data Could Make or Break BioNTech's Oncology Ambitions as Board Refresh Signals Era of Change

BioNTech’s stock is hovering just above its 52-week low at €75.60, the market’s verdict on an expensive and high-stakes transition that will test whether the company can successfully reinvent itself as a cancer specialist. The immediate catalyst for a potential rebound — or further decline — comes next week, when the biotech unveils phase 2 data from its ROSETTA-Lung-02 study at the American Society of Clinical Oncology (ASCO) annual meeting between May 29 and June 2.

The trial pits Pumitamig, an investigational immunotherapy, in combination with chemotherapy against the established standard-of-care pembrolizumab in first-line non-small cell lung cancer. A win in this head-to-head comparator design could dramatically shift market expectations for the oncology pipeline. A miss would put the €72.50 floor back in play. Shares have already surrendered roughly 13% over the past month, and at current levels they trade well below the 200-day moving average of about €87, underscoring the persistent bearish pressure.

Behind the near-term binary event lies a more structural transformation unfolding at the Mainz-based company. Co-founders Ugur Sahin and Özlem Türeci are set to leave by the end of 2026 to launch an independent mRNA innovation project. To stabilize the leadership transition, shareholders at the annual general meeting approved expanding the supervisory board from six to eight members. Helmut Jeggle assumes the chairmanship, while Iris Löw-Friedrich and Susanne Schaffert — both seasoned pharma executives with deep oncology experience — join the panel. Schaffert’s expertise in commercial launches and oncology sales directly supports the ambition to transition BioNTech into a fully-fledged oncology company with a marketed portfolio by 2030.

Should investors sell immediately? Or is it worth buying BioNTech?

The financial picture remains stark. Management reaffirmed its 2026 revenue guidance of €2.0 billion to €2.3 billion, reflecting the expected run-off of COVID-19 vaccine sales in the U.S. and Europe. To fund the late-stage pipeline, the company is burning cash at a rapid clip: adjusted R&D expenditure is forecast to reach as much as €2.5 billion this year, with selling and administrative costs adding hundreds of millions more. More than 25 phase 2 and phase 3 clinical studies are currently underway, spanning antibody-drug conjugates and mRNA immunotherapies.

Analysts are recalibrating their models accordingly. Berenberg recently trimmed its price target to $140, while Canaccord Genuity cut its own to $158 but maintained a buy rating. The optimism embedded in those targets hinges on clinical proof-of-concept for the oncology pipeline — exactly what the ASCO data set is designed to deliver.

The board overhaul and founder departure timeline give investors a clearer picture of the runway ahead. BioNTech must generate commercial value from its pipeline before the revenue from its legacy COVID franchise fully evaporates and before its founders exit the stage. The next few days of data readouts will provide the most tangible evidence yet of whether that ambitious timetable is achievable.

Ad

BioNTech Stock: New Analysis - 18 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | PUMITAMIG | boerse | 69367590 |